根据名称进行药物检索

Equetro 与 Methenamine, Sodium Phosphate Monobasic, Phenyl Salicylate, Methylene Blue, and Hyoscyamine

Equetro 与 Methenamine, Sodium Phosphate Monobasic, Phenyl Salicylate, Methylene Blue, and Hyoscyamine互相作用以及同时服用的可能性。

检测结果:

Equetro <> Methenamine, Sodium Phosphate Monobasic, Phenyl Salicylate, Methylene Blue, and Hyoscyamine

现实性: 26.06.2023 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

使用亚甲基蓝色一起卡马西平，不建议。结合这些药物可以增加风险的一个罕见的，但严重的疾病叫做血清素综合症，其中可能包括的症状，如混乱、幻觉、扣押、极端变化血压，心率增加、发烧、多汗、颤抖或颤抖、视力模糊，肌肉痉挛或僵硬、震颤、不协调、胃痉挛、恶心、呕吐、腹泻。严重的情况下可能导致昏迷甚至死亡。在一般情况下，应至少等待14天之后，停止甲基蓝在你开始处理与卡马西平。相反，如果最近在卡马西平，现在是开始治疗与亚甲基蓝色，你应该检查你的医生或药剂师看到你多久之前应等待这是为你的安全使用亚甲基蓝色，因为某些药物可能需要一段时间才能明确自己的身体。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

禁忌:共同给予的单胺氧化酶抑制剂(单胺氧化抑制剂)和二苯并氮杂的衍生物(例如，三和四环抗抑郁药，知识产权、卡马西平)可以产生明显的不良反应，包括恶心、呕吐、冲洗、头晕、震颤、肌阵挛、刚性、发汗解表、高热、自主的不稳定性、高血压的危机，弥散性血管内凝血、严重抽搐发作，昏迷和死亡。的确切机制的相互作用是未知的，但可能涉及过多的血清素的活动的中枢神经系统(即中，血清素综合征)。临床上的相互作用已经报道主要是在患者治疗单胺氧化抑制剂(包括可逆转、不可逆转的、选择性和非选择性)和三环抗抑郁药，特别是丙咪嗪和氯，这是最有力的血清素再吸收抑制剂的类。其他二苯并氮杂类药物也可以进行互动的基础上他们的结构和药理类似之处三环抗抑郁药，虽然数据有限。一个孤立的情况下已经报告了苯乙肼和知识产权，而没有任何案件已经被报道，卡马西平。相反，已经发表的报告援引一个缺乏相互作用以及成功使用的卡马西平与单胺氧化抑制剂.

管理：在一般情况下，二苯并氮杂的衍生物不应使用同时或单胺氧化抑制剂和其他药剂，拥有单胺氧化酶抑制剂的活动(例如痢特灵，亚甲基蓝、丙卡巴肼). 至少14天应之间停止的单胺氧化酶抑制剂疗法和治疗开始与三环抗抑郁药，反之亦然。虽然它仍然是有争议的，一些专家建议，某种单胺氧化抑制剂和三环抗抑郁药(除丙咪嗪和氯)可以一起用于处理难抑郁症的在特殊情况和密切监督，以下经验指导原则：在前三或单胺氧化酶抑制剂应当停止用于10至14天；这两种药物然后应该开始在低剂量；药物，不应给予非肠道；剂量变化，应在小的递增；血清素再吸收抑制剂不必须同时使用; 并应密切监测患者的迹象素的不利影响。

来源

de la Fuente JR, Berlanga C, Leon-Andrade C "Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports." J Clin Psychiatry 47 (1986): 40-1
Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2
Yatham LN, Barry S, Mobayed M, Dinan TG "Is the carbamazepine-phenelzine combination safe?." Am J Psychiatry 147 (1990): 367
White K, Simpson G "Combined MAOI-tricyclic antidepressant treatment: a reevaluation." J Clin Psychopharmacol 1 (1981): 264-82
Otte W, Birkenhager TK, van den Broek WW "Fatal interaction between tranylcypromine and imipramine." Eur Psychiatry 18 (2003): 264-5
Lader M "Combined use of tricyclic antidepressants and monoamine oxidase inhibitors." J Clin Psychiatry 44 (1983): 20-4
Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5
Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20
"Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
"Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763
Waghray SN, Francis K "Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics." J R Soc Med 77 (1984): 346
"Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.
Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13
Tackley RM, Tregaskis B "Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction." Anaesthesia 42 (1987): 760-3
Lydiard RB, White D, Harvey B, Taylor A "Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine." J Clin Psychopharmacol 7 (1987): 360
"Product Information. Emsam (selegiline)." Bristol-Myers Squibb, Princeton, NJ.
Wright SP "Hazards with monoamine-oxidase inhibitors: a persistent problem." Lancet 1 (1978): 284-5
Zetin M "Combined use of trimipramine and phenelzine in depression." J Nerv Ment Dis 170 (1982): 246-7
"Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
Kline SS, Mauro LS, Scala-Bennett DM, Zick D "Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death." Clin Pharm 8 (1989): 510-4
Joffe RT, Post RM, Uhde TW "Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine." Arch Gen Psychiatry 42 (1985): 738
"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA, North Wales, PA.
Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6
Graham PM, Potter JM, Paterson J "Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction." Lancet 2 (1982): 440
Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8
Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8
Pascual J, Combarros O, Berciano J "Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment." Clin Neuropharmacol 10 (1987): 565-7
Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):
"Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
Lefebvre H, Noblet C, Morre N, Wolf LM "Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline." Clin Endocrinol (Oxf) 42 (1995): 95-8
White K, Pistole T, Boyd JL "Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study." Am J Psychiatry 137 (1980): 1422-5
"Product Information. Methylene Blue (methylene blue)." American Regent Laboratories Inc, Shirley, NY.
Dardennes RM, Even C, Ballon N, Bange F "Serotonin syndrome caused by a clomipramine-moclobemide interaction." J Clin Psychiatry 59 (1998): 382-3
De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5
Spiker DG, Pugh DD "Combining tricyclic and monoamine oxidase inhibitor antidepressants." Arch Gen Psychiatry 33 (1976): 828-30
Ketter TA, Post RM, Parekh PI, Worthington K "Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression." J Clin Psychiatry 56 (1995): 471-5
"Product Information. Eldepryl (selegiline)." Somerset Pharmaceuticals Inc, Tampa, FL.
"Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
Kay DW, Garside RF, Fahy TJ "A double-blind trial of phenelzine and amitriptyline in depressed out- patients. A possible differential effect of the drugs on symptoms." Br J Psychiatry 123 (1973): 63-7
Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7
Feighner JP, Herbstein J, Damlouji N "Combined MAOI, TCA, and direct stimulant therapy of treatment- resistant depression." J Clin Psychiatry 46 (1985): 206-9
Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36
Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62

Equetro

非专利名称: carbamazepine

品牌: Carbatrol, Epitol, Equetro, Tegretol, Tegretol XR, Tegretol, Tegretol XR

同义词: 无

Equetro是什么？

Methenamine, Sodium Phosphate Monobasic, Phenyl Salicylate, Methylene Blue, and Hyoscyamine

非专利名称: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium biphosphate

品牌: Azuphen MB, Hyolev MB, Phosphasal, UR N-C, Uramit MB, Urelle, Uribel, Urimar-T, Urin D/S, Uro-L, Ustell, Utira-C, Uro-MP, Vilamit MB, Vilevev MB, UR N-C, Urelle, Uretron D/S, Urin DS, Uro-458, UroAv-81, UroAv-B, Uticap, Utrona-C

同义词: Hyoscyamine, methenamine, methylene blue, phenyl salicylate, sodium biphosphate

Methenamine, Sodium Phosphate Monobasic, Phenyl Salicylate, Methylene Blue, and Hyoscyamine是什么？

+ 添加药物全部删除

在药物相容性与互相作用的检测过程中使用下列的信息来源：Drugs.com, Rxlist.com, Webmd.com, Medscape.com。

公认药物相互作用的清单